Serra G E, Gustavino C, Serra Cervetti G G
Istituto Nazionale per la Ricerca sul Cancro, Genova.
Minerva Ginecol. 1992 Jan-Feb;44(1-2):15-8.
The study included 60 patients: 43 suffered from slight portio dysplasia (12 had HPV infection also), while 17 had moderate dysplasia (7 had HPV infections also). The treatment was carried out by self-administration in 3 stages: attack (50 mg of thymopentin by s.c. injection every day for two weeks); maintenance (50 mg of thymopentin by s.c. injection every other day for ten weeks); recall 6 months after (50 mg of thymopentin every day for 4 weeks). The drug was well tolerated by all of the patients and the recovery rate in a 9-months follow-up period was significantly higher versus an historical control group.
该研究纳入了60例患者:43例患有轻度宫颈发育异常(其中12例也感染了人乳头瘤病毒),而17例患有中度发育异常(其中7例也感染了人乳头瘤病毒)。治疗采用自我给药方式,分三个阶段进行:冲击阶段(皮下注射胸腺五肽50毫克,每天一次,持续两周);维持阶段(皮下注射胸腺五肽50毫克,隔天一次,持续十周);6个月后召回阶段(每天注射胸腺五肽50毫克,持续四周)。所有患者对该药物耐受性良好,在9个月的随访期内,恢复率明显高于历史对照组。